Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2003-05-07

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 16

Registration Number: NCT00060346

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States

and more 150 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: cytarabine
Drug: cyclophosphamide
Drug: methotrexate
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate

First Posted Date: 2003-04-25

Last Posted Date: 2018-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT00003311

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Phase 2

Conditions: Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-04-18

Last Posted Date: 2014-01-06

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 10

Registration Number: NCT00003163

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

First Posted Date: 2003-04-16

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 400

Registration Number: NCT00002822

Locations: 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-04-16

Last Posted Date: 2012-04-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 61

Registration Number: NCT00002945

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy in Treating Patients With Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim (G-CSF)
Biological: Bleomycin Sulfate (BLM)
Biological: Recombinant Interferon Alfa
Drug: Carmustine
Drug: Cytarabine (ARA-C)
Drug: Cisplatin (CDDP)
Drug: Etoposide (VP-16)
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Idarubicin
Drug: Melphalan
Drug: Leucovorin Calcium
Drug: mitoxantrone hydrochloride (DHAD)
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Methylprednisolone
Drug: Vincristine Sulfate
Radiation: Radiation Therapy

First Posted Date: 2003-04-16

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00002835

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2003-04-11

Last Posted Date: 2013-09-20

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 750

Registration Number: NCT00002701

Locations: 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹
Federico II University Medical School, Naples (Napoli), Italy
🇮🇹
Ospedale S. Gennora USL 42, Naples (Napoli), Italy

and more 68 locations